Peptide library › Metabolic & weight
Pemvidutide
Experimental weekly injection that acts on GLP-1 and glucagon receptors, studied for obesity and fatty liver disease.
What people use it for
- Obesity (in trials)
- Fatty liver disease, MASH (in trials)
What Pemvidutide does in the body
A dual agonist: the GLP-1 part reduces appetite, while the glucagon part increases energy use and fat burning in the liver. The aim is weight loss with a strong effect on liver fat and better preservation of muscle.
Strength of evidence
Moderate: Phase 2 trials showed meaningful weight loss and large drops in liver fat.
Look up the evidence
- Reviews on PubMed: Summaries of the published research
- Clinical trials on PubMed: Published studies in people
- ClinicalTrials.gov: Registered trials, past and ongoing
Live searches of official databases. New to the terms? See the glossary.
Reported side effects & risks
- Nausea and vomiting
- Diarrhoea or constipation
- Long-term safety unknown
Who should avoid it or take extra care
- Anyone outside a clinical trial
- Pregnancy or breastfeeding, unless a specialist advises it
Not a complete list. Check with a doctor or pharmacist about your own health and medicines.
Regulatory status
Investigational. Not approved by the FDA or any regulator.
How it's taken
Route: Injection under the skin, once weekly (in trials)
How long it lasts (half-life): Long-acting; designed for weekly dosing
Latest research & news
- Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASH
Clinical trial · Recruiting · Phase 3 · Updated · ClinicalTrials.gov · 17 Nov 2026
Picked automatically from PubMed, ClinicalTrials.gov and the FDA, and updated daily. Early, lab and animal studies often don't carry over to people.
Keep track of Pemvidutide privately
Fiala is a free app for logging doses, tracking vials and setting reminders. No account, and everything you log stays on your phone.
Open Pemvidutide in Fiala How to installMore in Metabolic & weight
- SemaglutideOnce-weekly GLP-1 receptor agonist for type 2 diabetes and chronic weight management.
- TirzepatideOnce-weekly dual GIP and GLP-1 receptor agonist for type 2 diabetes and weight management.
- RetatrutideExperimental triple GIP / GLP-1 / glucagon receptor agonist being studied for obesity.
- AOD-9604Modified fragment of human growth hormone once developed as an anti-obesity drug.
- LiraglutideOnce-daily GLP-1 receptor agonist; the predecessor of semaglutide.
- CagrilintideLong-acting amylin analog being studied for weight loss, mainly combined with semaglutide.
- MazdutideOnce-weekly dual GLP-1 and glucagon receptor agonist for weight management.
- SurvodutideExperimental once-weekly dual glucagon and GLP-1 receptor agonist being studied for obesity and fatty liver disease.
- DulaglutideOnce-weekly GLP-1 receptor agonist approved for type 2 diabetes.
- ExenatideThe first GLP-1 receptor agonist, originally found in Gila monster venom, approved for type 2 diabetes.
- PramlintideSynthetic version of the hormone amylin, used with mealtime insulin in diabetes.
- SetmelanotideMC4R agonist approved for rare genetic causes of severe obesity.
- 5-Amino-1MQSmall molecule sold alongside peptides for fat loss; blocks the enzyme NNMT. Not a peptide, and untested in people.
- AlbiglutideOnce-weekly GLP-1 medicine for type 2 diabetes, discontinued for business reasons in 2018.
- AmycretinExperimental single molecule that acts on both GLP-1 and amylin receptors, tested as a weekly injection and a daily tablet for weight loss.
- EfpeglenatideLong-acting experimental GLP-1 medicine that cut heart and kidney events in people with type 2 diabetes in a large trial.
- LixisenatideOnce-daily GLP-1 medicine for type 2 diabetes, now mainly used in a combined pen with insulin glargine.
- PetrelintideExperimental long-acting amylin analog given weekly for weight loss, aiming for fewer stomach side effects than GLP-1 drugs.
- Insulin analogsLab-modified versions of insulin that work faster or last longer, used to treat type 1 and type 2 diabetes.
- GlucagonEmergency hormone that quickly raises blood sugar during a severe hypo; also used to relax the gut during scans.
- DasiglucagonStable, ready-to-use version of glucagon for treating severe low blood sugar in people with diabetes.